Overview
BTT-1023 in Rheumatoid Arthritis
Status:
Completed
Completed
Trial end date:
2009-11-01
2009-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Biotie Therapies Corp.
Criteria
Inclusion Criteria:- adult-onset rheumatoid arthritis
Exclusion Criteria:
-